Montoya GC, Hernández LA, Poblano MM, Olvera GC, Aguirre SJ, Granillo JF

Idioma: Español
Referencias bibliográficas: 41
Paginas: 130-141
Archivo PDF: 173.76 Kb.

RESUMEN

Introducción: Las estatinas tienen efectos antiinflamatorios, se han propuesto como estrategia terapéutica en el paciente séptico. Objetivo: Conocer el efecto antiinflamatorio de las estatinas en el paciente séptico. Metodología: Estudio prospectivo, longitudinal, experimental. Placebo controlado. Resultados: Se incluyeron 40 pacientes. Se aleatorizaron en dos grupos. El grupo tratamiento recibió 80 mg de simvastatina, durante 14 días. Se determinaron marcadores inflamatorios: velocidad de sedimentación globular (VSG), proteína C-reactiva (PCR), antitrombina III (AT III). Se observó disminución de VSG 19 (14-23), 36 (27-50) (p ‹ 0.01). PCR 6 (4-9), 13 (9-18), (p ‹ 0.01), incrementó AT III III 57 (49-65), 36 (29-49) (p ‹ 0.01) a partir del 5º día. Disminuyó días de venti-mec (VM). 10(2-12), 16 (4-18) (p ‹ 0.04). Y días de estancia en UCI 15 (14-16), 22 (18-26), (p ‹ 0.01). Conclusión: Las estatinas disminuyeron la respuesta inflamatoria, se redujo días de VM y estancia UCI.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Martin GS, Maninno DM, Eaton S et al. The epidemiology of Sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.

2. Bone RC, Balk RA, Cerra FB. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644.

3. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.

4. Hotchkiss R, Karl I. The Pathophysiology and Treatment of Sepsis. N Engl J Med 2003;348:138-50.

5. Russell J. Management of Sepsis. N Engl J Med 206;355:1699-713.

6. Ferreira FL, Bota DP, Bross A et al. Serial Evaluation of the SOFA score to predict Outcome in Critically Ill Patients. JAMA 2001;286:1754-1758.

7. De Leon Rosales SP. Prevalence of Infections in Intensive Care Units in Mexico: A Multicenter Study. Critical Care Med 2000;28:1316-1321.

8. Calabrò P, Yeh E. The Pleiotropic Effects: of Statins. Curr Opin Cardiol 2005;20:541-546.

9. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscl Thromb Vasc Biol 2001;21:1712-1719.

10. Majumdar S, McAlister FA, Eurich DT, Padwa RS, Marrie TTJ. Statins and outcomes in patients admitted to hospital with community acquired pneumoniae: population based prospective cohort study. BMJ 2006;333:999-1003.

11. Almong Y. Statins, inflammation, and sepsis, hypothesis. Chest 2003;124:740-743.

12. Chua D, Tsang Rs, Kuo IF. The role of statins therapy in sepsis. Ann Pharmacother 2007;41:647-52.

13. Almog Y, Shefer A, Novack V et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-885.

14. Schönbeck U, Lobby P. Inflammation. Immunity and HMG-CoA reductase inhibitors statins as anti-inflammatory agents? Circulation 2004;109:18-26.

15. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statin on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352-1357.

16. Schmidt H, Hennen R, Keller A et al. Association of statins therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 2006;32:1248-51.

17. Kruger P FK, Cook D, Jones M, Nimmo G. Statins therapy is associated with fewer deaths in patients with bacteremia. Intensive Care Med 2006;32:75-79.

18. Hackman DG MM, Li P, Redelmeir DA. Statins and sepsis in patients with cardiovascular disease: a population based cohort analysis. Lancet 2006;367:413-418.

19. Thomsen RW, Hundborg HH, Johnsen SP et al. Statins use and mortality with 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34: 1080-06.

20. Whtite B, Perry D. Acquired antithrombin deficiency in sepsis. british journal of haematology 2001;112:26-31.

21. Pettilä V, Pentt J, Pettilä M et al. Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 2002;30:271-275.

22. Lobo SM, Lobo FR, Bota DP et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003;123:2043-49.

23. Chan KY, Bouchers ES, Gandhi PJ, Silva MA. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Sys Pharm 2004;61:1676-81.

24. Undas A, Brummel-Ziendins K, Mann K. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25:287-294.

25. Mach F. Statins as immunomodulatory agents. Circulation 2004;109:15-17.

26. Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002;30:302-312.

27. Vincent JL. Microvascular endothelial dysfunction a renewed appreciation of sepsis pathophysiology. Crit Care 2001;5(suppl 2):S1-S5.

28. Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol 2007;28:88-98.

29. Terbalanche M, Almong Y et al. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007;7:358-68.

30. Pleiner J, Schaller G, Mittermayer F et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004;110:3349-54.

31. Giusti-Paiva A, Martinez MR, Felix JV et al. Simvastatin decreased nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 2004;21:271-75.

32. Landmesser U, Bahlmann F, Muller M et al. Simvastatin versus ezetimibe: pleiotropic and lipid lowering effects on endothelial function in humans. Circulation 2005;111:2356-2363.

33. Merx MW, Liehn EA, Janssens U. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004;109:2560-2565.

34. Marshall JC. Sepsis: current status, future aspects. Curr Opin Crit Care 2004;10:250-264.

35. Terblanche M, Almong Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis 2006;6:242-248.

36. Niessner A, Steiner S, Speidl WS et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006;189:408-13.

37. Steiner S, Speidl WS, Pleiner J et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005;111:1841-46.

38. Veillard NR, Braunersreuther V, Arnaud C et al. Simvastatin modulates chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-58.

39. Membreño JP. Marcadores de activación endotelial y coagulación en pacientes con síndrome de respuesta inflamatoria sistémica por sepsis. The ABC Medical Center 2008:1-50.

40. Rivers E, Nguyen B, Havstad S. Early goal direct therapy in the treatment of severe sepsis and septic shcock. N Engl J Med 2001;344:699-709.

41. Gao F, Linhartova L, Johnoson McD. Statins and sepsis. Br J Anaesth 2008;100:288-98.